Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More IDO Issues: NewLink Drops Pancreatic Cancer Indication For Indoximod

Executive Summary

NewLink has scrapped plans to explore its IDO inhibitor in pancreatic cancer – more bad news for a drug class that has suffered several setbacks recently.

Advertisement

Related Content

iTeos Says Adios To IDO And Eyes US IPO
NewLink CEO Reflects On Golden Age And Rapid Fall Of IDO
A Wake For IDO: Bristol Ends Registrational Trials Of High-Priced Flexus Drug
Incyte/Merck's ECHO-301 Failure Casts More Shadow On IDO Space

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123035

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel